Clinical Psychopharmacology and Neuroscience indexed in CAS, DOI/Crossref, EMBASE, Korea Citation Index (KCI), KoreaMed, Korea Medical Citation Index (KoMCI), PubMed, PubMed Central (PMC), SCOPUS, SCI-expanded (SCIE), and Google Scholar:eISSN 2093-4327   pISSN 1738-1088

Download original image
Fig. 2. Low doses of pentoxifylline (PTX) partly prevent the impairment of memory induced by hypoxic-ischemic brain injury. Group means latencies (A), path length (B), and mean distance to the hidden platform location (C) for each of the 16 training trials across 4 consecutive days showed improvement for all groups with training. Group (n = 5) ×day (D, n = 4) × trial (T, n = 4) ANOVAs revealed significant interactions of group with day and trial for escape latency and the mean distance to the platform (A and C), but only with trial for path length (B). Note that both the hypoxic-ischemic encephalopathy (HIE) group and PTX100 group require more time to find the platform (A) and moved more distance to the platform location (C) relative to the control, sham and PTX60 groups in most of the daily trials. Further analyzed path lengths by taking the average across trials in each day are shown in Figure 3. (D) Mean swim speed of control, sham and experimental groups for each of the 16 training trials across 4 consecutive days. Circles for control (n = 17), sham (n = 13), HIE (n = 16), and squares for PTX60 (n = 20) and PTX100 (n = 11) are mean ± standard error.

*p < 0.05 versus control group; p < 0.05 versus sham group; p < 0.05 versus control and sham groups; §p < 0.05 versus control, sham and PTX100 groups.

Clinical Psychopharmacology and Neuroscience 2019;17:388~399 https://doi.org/10.9758/cpn.2019.17.3.388
© Clin Psychopharmacol Neurosci